Wielenga VJ - Search Results

1

p53 and CD44 as clinical markers of tumour progression in colorectal carcinogenesis.

Mulder JW, Wielenga VJ, Pals ST, Offerhaus GJ. Mulder JW, et al. Among authors: wielenga vj. Histochem J. 1997 Jun;29(6):439-52. doi: 10.1023/a:1026403404652. Histochem J. 1997. PMID: 9248852 Review.

2

Expression of CD44 splice variants during lymphocyte activation and tumor progression.

Griffioen AW, Horst E, Heider KH, Wielenga VJ, Adolf GR, Herrlich P, Pals ST. Griffioen AW, et al. Among authors: wielenga vj. Cell Adhes Commun. 1994 Jul;2(3):195-200. doi: 10.3109/15419069409004437. Cell Adhes Commun. 1994. PMID: 7530151

3

Expression of mutant p53 protein and CD44 variant proteins in colorectal tumorigenesis.

Mulder JW, Wielenga VJ, Polak MM, van den Berg FM, Adolf GR, Herrlich P, Pals ST, Offerhaus GJ. Mulder JW, et al. Among authors: wielenga vj. Gut. 1995 Jan;36(1):76-80. doi: 10.1136/gut.36.1.76. Gut. 1995. PMID: 7534253 Free PMC article.

4

Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression.

Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM, Ponta H, Herrlich P, Pals ST. Wielenga VJ, et al. Cancer Res. 1993 Oct 15;53(20):4754-6. Cancer Res. 1993. PMID: 7691404

5

CD44 splice variants as prognostic markers in colorectal cancer.

Wielenga VJ, van der Voort R, Mulder JW, Kruyt PM, Weidema WF, Oosting J, Seldenrijk CA, van Krimpen C, Offerhaus GJ, Pals ST. Wielenga VJ, et al. Scand J Gastroenterol. 1998 Jan;33(1):82-7. doi: 10.1080/00365529850166257. Scand J Gastroenterol. 1998. PMID: 9489913

6

CD44 expression predicts disease outcome in localized large B cell lymphoma.

Drillenburg P, Wielenga VJ, Kramer MH, van Krieken JH, Kluin-Nelemans HC, Hermans J, Heisterkamp S, Noordijk EM, Kluin PM, Pals ST. Drillenburg P, et al. Among authors: wielenga vj. Leukemia. 1999 Sep;13(9):1448-55. doi: 10.1038/sj.leu.2401490. Leukemia. 1999. PMID: 10482998 Clinical Trial.

7

CD44 glycoproteins in colorectal cancer: expression, function, and prognostic value.

Wielenga VJ, van der Neut R, Offerhaus GJ, Pals ST. Wielenga VJ, et al. Adv Cancer Res. 2000;77:169-87. doi: 10.1016/s0065-230x(08)60787-3. Adv Cancer Res. 2000. PMID: 10549358 Review. No abstract available.

8

Expression of c-Met and heparan-sulfate proteoglycan forms of CD44 in colorectal cancer.

Wielenga VJ, van der Voort R, Taher TE, Smit L, Beuling EA, van Krimpen C, Spaargaren M, Pals ST. Wielenga VJ, et al. Am J Pathol. 2000 Nov;157(5):1563-73. doi: 10.1016/S0002-9440(10)64793-1. Am J Pathol. 2000. PMID: 11073815 Free PMC article.

9

Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway.

Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R, Clevers H, Pals ST. Wielenga VJ, et al. Am J Pathol. 1999 Feb;154(2):515-23. doi: 10.1016/S0002-9440(10)65297-2. Am J Pathol. 1999. PMID: 10027409 Free PMC article.

10

Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met.

van der Voort R, Taher TE, Wielenga VJ, Spaargaren M, Prevo R, Smit L, David G, Hartmann G, Gherardi E, Pals ST. van der Voort R, et al. Among authors: wielenga vj. J Biol Chem. 1999 Mar 5;274(10):6499-506. doi: 10.1074/jbc.274.10.6499. J Biol Chem. 1999. PMID: 10037743 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11 results

Search Page

Filters